Jefferies Financial Group Inc. Has $1.67 Million Stock Holdings in ResMed Inc. (NYSE:RMD)

Jefferies Financial Group Inc. cut its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 46.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 7,306 shares of the medical equipment provider's stock after selling 6,271 shares during the period. Jefferies Financial Group Inc.'s holdings in ResMed were worth $1,671,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. ABLE Financial Group LLC lifted its position in ResMed by 2.8% during the 4th quarter. ABLE Financial Group LLC now owns 2,639 shares of the medical equipment provider's stock valued at $604,000 after purchasing an additional 72 shares during the period. Forum Financial Management LP acquired a new position in ResMed during the 4th quarter valued at about $273,000. Toronto Dominion Bank lifted its position in ResMed by 4.3% during the 4th quarter. Toronto Dominion Bank now owns 51,349 shares of the medical equipment provider's stock valued at $11,743,000 after purchasing an additional 2,099 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of ResMed in the 4th quarter valued at about $831,000. Finally, Public Employees Retirement System of Ohio increased its stake in shares of ResMed by 4.7% in the 4th quarter. Public Employees Retirement System of Ohio now owns 57,717 shares of the medical equipment provider's stock valued at $13,199,000 after acquiring an additional 2,602 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total value of $455,420.00. Following the completion of the sale, the director now owns 75,218 shares of the company's stock, valued at approximately $17,127,890.78. This represents a 2.59% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $239.31, for a total value of $2,332,075.95. Following the completion of the sale, the insider now directly owns 9,725 shares of the company's stock, valued at approximately $2,327,289.75. The trade was a 50.05% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,949 shares of company stock valued at $11,822,260. 0.71% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RMD has been the subject of a number of recent analyst reports. Piper Sandler lowered their price target on ResMed from $260.00 to $248.00 and set a "neutral" rating for the company in a research note on Thursday, April 24th. Citigroup raised ResMed from a "neutral" rating to a "buy" rating in a research note on Wednesday, March 5th. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th. UBS Group lowered their price target on ResMed from $290.00 to $285.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Finally, Mizuho set a $265.00 price target on ResMed in a research note on Wednesday, April 16th. One analyst has rated the stock with a sell rating, six have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, ResMed currently has a consensus rating of "Moderate Buy" and an average price target of $259.33.

ResMed Stock Down 0.2%

NYSE:RMD traded down $0.50 during trading hours on Friday, reaching $244.62. 1,060,298 shares of the stock were exchanged, compared to its average volume of 1,022,899. ResMed Inc. has a twelve month low of $179.42 and a twelve month high of $263.05. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.33 and a quick ratio of 2.29. The firm has a 50 day moving average of $229.74 and a 200 day moving average of $234.23. The stock has a market cap of $35.87 billion, a PE ratio of 28.88, a PEG ratio of 1.53 and a beta of 0.78.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 earnings per share for the quarter, topping analysts' consensus estimates of $2.36 by $0.01. ResMed had a return on equity of 26.17% and a net margin of 25.34%. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the prior year, the firm posted $2.13 EPS. The business's revenue was up 7.9% on a year-over-year basis. On average, equities analysts expect that ResMed Inc. will post 9.47 earnings per share for the current year.

ResMed Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend is Thursday, May 8th. ResMed's payout ratio is presently 23.79%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.